OncoMatch/Clinical Trials/NCT06261125
Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)
Is NCT06261125 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Adebrelimab and Lenvatinib for hepatocellular carcinoma.
Treatment: Adebrelimab · Lenvatinib — Abdominal lymph node metastasis (LNM) is one of the major modes of extrahepatic metastasis in hepatocellular carcinoma (HCC). Immunotherapy targeting the PD-1/PD-L1 checkpoints combined with targeted therapy is the standard treatment for HCC with abdominal LNM, but the outcome remains very poor, with an objective response rate of 5% to 30%. Previous studies have demonstrated that stereotactic body radiotherapy (SBRT) is an effective local treatment for HCC with abdominal LNM, with a high response rate of 60% to 80%. However, intrahepatic dissemination and distant metastasis remains the major recurrence pattern after SBRT in these patients, suggesting radiotherapy should be combined with systematic treatment. Recently, the combination of immunotherapy with SBRT has shown promising activity in HCC. The aim of this study was to investigate the efficacy and safety of SBRT followed by adebrelimab (an anti-PD-L1 antibody) and lenvatinib in HCC patients with portal abdominal LNM.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: lenvatinib (lenvatinib)
Exception: patients who could not be tolerated
Patients who have previously been treated with lenvatinib or PD-1/PD-L1 antibody but could not be tolerated
Cannot have received: anti-PD-1/PD-L1 therapy
Exception: patients who could not be tolerated
Patients who have previously been treated with lenvatinib or PD-1/PD-L1 antibody but could not be tolerated
Cannot have received: abdominal radiotherapy
A history of abdominal radiotherapy
Lab requirements
Blood counts
WBC ≥ 3.0×10^9/L, ANC ≥ 1.5×10^9/L; platelets ≥ 50×10^9/L; hemoglobin ≥ 9g/dL
Kidney function
serum creatinine ≤ 1.5×ULN or creatinine clearance rate >60 mL/min
Liver function
Child-Pugh class A liver function; total bilirubin ≤ 1.5×ULN, ALT, AST and/or AKP ≤ 2.5×ULN; serum albumin ≥ 2.8g/dL
Child-Pugh class A liver function; normal liver volume >700 ml; WBC ≥ 3.0×10^9/L, ANC ≥ 1.5×10^9/L; platelets ≥ 50×10^9/L; hemoglobin ≥ 9g/dL; serum albumin ≥ 2.8g/dL; total bilirubin ≤ 1.5×ULN, ALT, AST and/or AKP ≤ 2.5×ULN; serum creatinine ≤ 1.5×ULN or creatinine clearance rate >60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify